Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed the day trading at $61.14 up 3.14% from the previous closing price of $59.28. In other words, the price has increased by $3.14 from its previous closing price. On the day, 4.24 million shares were traded. BMRN stock price reached its highest trading level at $61.785 during the session, while it also had its lowest trading level at $59.24.
Ratios:
For a better understanding of BMRN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.12. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 4.83. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On November 06, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $61. On September 08, 2025, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $60.H.C. Wainwright initiated its Neutral rating on September 08, 2025, with a $60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 11745870848 and an Enterprise Value of 10872272896. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.91, and their Forward P/E ratio for the next fiscal year is 13.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.81 while its Price-to-Book (P/B) ratio in mrq is 1.94. Its current Enterprise Value per Revenue stands at 3.514 whereas that against EBITDA is 13.692.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.27, which has changed by -0.11548793 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $73.51, while it has fallen to a 52-week low of $50.76. The 50-Day Moving Average of the stock is 13.38%, while the 200-Day Moving Average is calculated to be 5.73%.
Shares Statistics:
Over the past 3-months, BMRN traded about 2.92M shares per day on average, while over the past 10 days, BMRN traded about 4066750 shares per day. A total of 192.10M shares are outstanding, with a floating share count of 190.03M. Insiders hold about 1.09% of the company’s shares, while institutions hold 96.59% stake in the company. Shares short for BMRN as of 1764288000 were 8230587 with a Short Ratio of 2.82, compared to 1761868800 on 9861372. Therefore, it implies a Short% of Shares Outstanding of 8230587 and a Short% of Float of 5.4899998.
Earnings Estimates
. The current assessment of Biomarin Pharmaceutical Inc (BMRN) involves the perspectives of 18.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $1.26, with high estimates of $1.42 and low estimates of $1.07.
Analysts are recommending an EPS of between $3.77 and $3.26 for the fiscal current year, implying an average EPS of $3.57. EPS for the following year is $5.31, with 15.0 analysts recommending between $6.09 and $4.67.
Revenue Estimates
20 analysts predict $822.12M in revenue for. The current quarter. It ranges from a high estimate of $852M to a low estimate of $788M. As of. The current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $747.31MFor the next quarter, 20 analysts are estimating revenue of $818.32M. There is a high estimate of $867M for the next quarter, whereas the lowest estimate is $787M.
A total of 24 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.2B, while the lowest revenue estimate was $3.13B, resulting in an average revenue estimate of $3.17B. In the same quarter a year ago, actual revenue was $2.85BBased on 18 analysts’ estimates, the company’s revenue will be $3.39B in the next fiscal year. The high estimate is $3.64B and the low estimate is $3.2B.
